Searched for: in-biosketch:true
person:segevd01
Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series [Letter]
Connolly, Caoilfhionn M; Teles, Mayan; Frey, Sarah; Boyarsky, Brian J; Alejo, Jennifer L; Werbel, William A; Albayda, Jemima; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline; Segev, Dorry L; Paik, Julie J
PMID: 34493492
ISSN: 1468-2060
CID: 5127632
Antibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients [Letter]
Qin, Caroline X; Auerbach, Scott R; Charnaya, Olga; Danziger-Isakov, Lara A; Ebel, Noelle H; Feldman, Amy G; Hsu, Evelyn K; McAteer, John; Mohammad, Saeed; Perito, Emily R; Thomas, Ashley M; Chiang, Teresa P Y; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Mogul, Douglas B
PMCID:8653193
PMID: 34517430
ISSN: 1600-6143
CID: 5127652
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series [Letter]
Connolly, Caoilfhionn M; Chiang, Teresa Po-Yu; Boyarsky, Brian J; Ruddy, Jake A; Teles, Mayan; Alejo, Jennifer L; Massie, Allan; Werbel, William A; Shah, Ami A; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline; Segev, Dorry L; Paik, Julie J
PMID: 34556484
ISSN: 1468-2060
CID: 5127672
Cognitive Impairment and Physical Frailty in Patients With Cirrhosis
Berry, Kacey; Duarte-Rojo, Andres; Grab, Joshua D; Dunn, Michael A; Boyarsky, Brian J; Verna, Elizabeth C; Kappus, Matthew R; Volk, Michael L; McAdams-DeMarco, Mara; Segev, Dorry L; Ganger, Daniel R; Ladner, Daniela P; Shui, Amy; Tincopa, Monica A; Rahimi, Robert S; Lai, Jennifer C
Physical frailty and impaired cognition are common in patients with cirrhosis. Physical frailty can be assessed using performance-based tests, but the extent to which impaired cognition may impact performance is not well characterized. We assessed the relationship between impaired cognition and physical frailty in patients with cirrhosis. We enrolled 1,623 ambulatory adult patients with cirrhosis waiting for liver transplantation at 10 sites. Frailty was assessed with the liver frailty index (LFI; "frail," LFI ≥ 4.4). Cognition was assessed at the same visit with the number connection test (NCT); continuous "impaired cognition" was examined in primary analysis, with longer NCT (more seconds) indicating worse impaired cognition. For descriptive statistics, "impaired cognition" was NCT ≥ 45 seconds. Linear regression associated frailty and impaired cognition; competing risk regression estimated subhazard ratios (sHRs) of wait-list mortality (i.e., death/delisting for sickness). Median NCT was 41 seconds, and 42% had impaired cognition. Median LFI (4.2 vs. 3.8) and rates of frailty (38% vs. 20%) differed between those with and without impaired cognition. In adjusted analysis, every 10-second NCT increase associated with a 0.08-LFI increase (95% confidence interval [CI], 0.07-0.10). In univariable analysis, both frailty (sHR, 1.63; 95% CI, 1.43-1.87) and impaired cognition (sHR, 1.07; 95% CI, 1.04-1.10) associated with wait-list mortality. After adjustment, frailty but not impaired cognition remained significantly associated with wait-list mortality (sHR, 1.55; 95% CI, 1.33-1.79). Impaired cognition mediated 7.4% (95% CI, 2.0%-16.4%) of the total effect of frailty on 1-year wait-list mortality. Conclusion: Patients with cirrhosis with higher impaired cognition displayed higher rates of physical frailty, yet frailty independently associated with wait-list mortality while impaired cognition did not. Our data provide evidence for using the LFI to understand mortality risk in patients with cirrhosis, even when concurrent impaired cognition varies.
PMCID:8710786
PMID: 34558844
ISSN: 2471-254x
CID: 5127682
Offer Acceptance Patterns for Liver Donors Aged 70 and Older
Haugen, Christine E; Bowring, Mary G; Jackson, Kyle R; Garonzik-Wang, Jacqueline; Massie, Allan B; Chiang, Teresa Po-Yu; Philosophe, Benjamin; Segev, Dorry L; Halazun, Karim J
Despite a documented survival benefit, older liver donor (OLD, age ≥70) graft offers are frequently declined, with utilization worsening over the last decade. To understand how offer acceptance varies by center, we studied 1113 eventually transplanted OLD grafts from 2009 to 2017 using Scientific Registry of Transplant Recipients (SRTR) data and random-intercept multilevel logistic regression. To understand how center-level acceptance of OLD graft offers might be associated with waitlist and posttransplant outcomes, we studied all adult, actively listed, liver-only candidates and recipients during the study period using Poisson regression (transplant rate), competing risks regression (waitlist mortality), and Cox regression (posttransplant mortality). Among 117 centers, OLD offer acceptance ranged from 0 (23 centers) to 95 acceptances, with a median odds ratio of 2.88. Thus, a candidate may be three times as likely to receive an OLD graft simply by listing at a different center. Centers in the highest quartile (Q4) of OLD acceptance (accepted 39% of OLD offers) accepted more nationally shared organs (Q4 versus Q1: 14.1% versus 0.0%, P < 0.001) and had higher annual liver transplant volume (Q4 versus Q1: 80 versus 21, P < 0.001). After adjustment, nationally shared OLD offers (adjusted odds ratio [aOR]: 0.16, 95% confidence interval [CI]: 0.13-0.20) and offers to centers with higher median Model for End-Stage Liver Disease (MELD) at transplant (aOR: 0.74, 95% CI: 0.62-0.87) were less likely to be accepted. OLD offers to centers with higher annual transplant volume were more likely to be accepted (aOR: 1.21, 95% CI: 1.14-1.30). Additionally, candidates listed at centers within the highest quartile of OLD graft offer acceptance had higher deceased donor liver transplantation (DDLT) rates (adjusted incidence rate ratio: 1.45, 95% CI: 1.41-1.50), lower waitlist mortality (adjusted subhazard ratio: 0.76, 95% CI: 0.72-0.76), and similar posttransplant survival (adjusted hazard ratio: 0.93, 95% CI: 0.86-1.01) when compared with those listed at centers in the lowest quartile of OLD graft offer acceptance. The wide variation in OLD offer acceptance supports the need for optimizing the organ offer process and efficiently directing OLD offers to centers more likely to use them.
PMID: 34559954
ISSN: 1527-6473
CID: 5127692
Frailty and the Risk of Acute Kidney Injury Among Patients With Cirrhosis
Cullaro, Giuseppe; Verna, Elizabeth C; Duarte-Rojo, Andres; Kappus, Matthew R; Ganger, Daniel R; Rahimi, Robert S; Boyarsky, Brian; Segev, Dorry L; McAdams-DeMarco, Mara; Ladner, Daniela P; Volk, Michael L; Hsu, Chi-Yuan; Lai, Jennifer C
Acute kidney injury (AKI) and frailty are major drivers of outcomes among patients with cirrhosis. What is unknown is the impact of physical frailty on the development of AKI. We included adults with cirrhosis without hepatocellular carcinoma listed for liver transplantation at nine US centers (n = 1,033). Frailty was assessed using the Liver Frailty Index (LFI); "frail" was defined by LFI ≥ 4.2. Chronic kidney disease as a baseline estimated glomerular filtration rate <60 mL/min/1.73 m2 . Our primary outcome, AKI, was defined as an increase in serum creatinine ≥0.3 mg/dL or a serum creatinine ≥1.5-fold increase. Wait-list mortality was defined as either a death on the wait list or removal for being too sick. We performed Cox regression analyses to estimate the hazard ratios (HRs) for AKI and wait-list mortality. Of 1,033 participants, 41% were frail and 23% had CKD. Twenty-one percent had an episode of AKI during follow-up. Frail versus nonfrail patients were more likely to develop AKI (25% vs. 19%) and wait-list mortality (21% vs. 13%) (P < 0.01 for each). In multivariable Cox regression, each of the following groups was associated with a higher risk of AKI as compared with not frail/no CKD: frail/no CKD (adjusted HR [aHR] = 1.87, 95% confidence interval [CI] = 1.29-2.72); not frail/CKD (aHR = 4.30, CI = 2.88-6.42); and frail/CKD (aHR = 4.85, CI = 3.33-7.07). We use a readily available metric, LFI, to identify those patients with cirrhosis most at risk for AKI. We highlight that serum creatinine and creatinine-based estimations of glomerular filtration rate may not fully capture a patient's vulnerability to AKI among the frail phenotype. Conclusion: Our work lays the foundation for implementing physical frailty in clinical practice to identify AKI earlier, implement reno-protective strategies, and expedite liver transplantation.
PMID: 34676697
ISSN: 2471-254x
CID: 5127722
Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients
Alejo, Jennifer L; Mitchell, Jonathan; Chiang, Teresa Po-Yu; Abedon, Aura Toma; Sidoti, Carolyn N; Boyarsky, Brian J; Avery, Robin K; Tobian, Aaron A R; Levan, Macey L; Warren, Daniel S; Massie, Allan B; Garonzik-Wang, Jacqueline M; Segev, Dorry Lidor; Werbel, William A
PMCID:8667681
PMID: 34711780
ISSN: 1534-6080
CID: 5127732
Replacing Unintentional Weight Loss with CT-Assessed Sarcopenia in the Physical Frailty Phenotype for Kidney Transplant Recipients [Meeting Abstract]
Chen, Xiaomeng; Shafaat, Omid; Liu, Yi; King, Elizabeth; Weiss, Clifford; Xue, Qian-Li; Walston, Jeremy; Segev, Dorry; McAdams-DeMarco, Mara
ISI:000739470700120
ISSN: 1600-6135
CID: 5133642
Perception of Transplant Surgery and the Pursuit of a Career in Transplant Surgery Among US General Surgery Residents [Meeting Abstract]
Loseth, Caitlin; Qin, Caroline; Zeiser, Laura; Segev, Dorry; Dageforde, Leigh Anne; Watkins, Anthony; Collins, Kelly; Glorioso, Jaime; Quillin, R. Cutler, III; Garonzik-Wang, Jacqueline; Tevar, Amit
ISI:000739470700138
ISSN: 1600-6135
CID: 5133652
Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study
Lai, Jennifer C; Shui, Amy M; Duarte-Rojo, Andres; Ganger, Daniel R; Rahimi, Robert S; Huang, Chiung-Yu; Yao, Frederick; Kappus, Matthew; Boyarsky, Brian; McAdams-Demarco, Mara; Volk, Michael L; Dunn, Michael A; Ladner, Daniela P; Segev, Dorry L; Verna, Elizabeth C; Feng, Sandy
BACKGROUND AND AIMS/OBJECTIVE:Frailty is a well-established risk factor for poor outcomes in patients with cirrhosis awaiting liver transplantation (LT), but whether it predicts outcomes among those who have undergone LT is unknown. APPROACH AND RESULTS/UNASSIGNED:Adult LT recipients from 8 US centers (2012-2019) were included. Pre-LT frailty was assessed in the ambulatory setting using the Liver Frailty Index (LFI). "Frail" was defined by an optimal cut point of LFI ≥ 4.5. We used the 75th percentile to define "prolonged" post-LT length of stay (LOS; ≥12 days), intensive care unit (ICU) days (≥4 days), and inpatient days within 90 post-LT days (≥17 days). Of 1166 LT recipients, 21% were frail pre-LT. Cumulative incidence of death at 1 and 5 years was 6% and 16% for frail and 4% and 10% for nonfrail patients (overall log-rank p = 0.02). Pre-LT frailty was associated with an unadjusted 62% increased risk of post-LT mortality (95% CI, 1.08-2.44); after adjustment for body mass index, HCC, donor age, and donation after cardiac death status, the HR was 2.13 (95% CI, 1.39-3.26). Patients who were frail versus nonfrail experienced a higher adjusted odds of prolonged LT LOS (OR, 2.00; 95% CI, 1.47-2.73), ICU stay (OR, 1.56; 95% CI, 1.12-2.14), inpatient days within 90 post-LT days (OR, 1.72; 95% CI, 1.25-2.37), and nonhome discharge (OR, 2.50; 95% CI, 1.58-3.97). CONCLUSIONS:Compared with nonfrail patients, frail LT recipients had a higher risk of post-LT death and greater post-LT health care utilization, although overall post-LT survival was acceptable. These data lay the foundation to investigate whether targeting pre-LT frailty will improve post-LT outcomes and reduce resource utilization.
PMID: 34862808
ISSN: 1527-3350
CID: 5127772